2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms
8
Primary Myelofibrosis
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Solid Tumors
4
Leukemia, Myeloid, Acute
4
Neoplasm Metastasis
3
Lymphoma
3
Small Cell Lung Carcinoma
2
Recurrence
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Leukemia, B-Cell
2
Leukemia
2
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Solid Tumor
1
Sezary Syndrome
1
Prostatic Neoplasms
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Cyclophosphamide
14
Dexamethasone
13
Vincristine
11
Cytarabine
11
Methotrexate
9
venetoclax
7
Inotuzumab Ozogamicin
7
Doxorubicin
7
pegaspargase
6
merphos
6
blinatumomab
6
Prednisone
6
dexamethasone acetate
5
dexamethasone 21-phosphate
5
Mercaptopurine
5
Calcium Dobesilate
5
prednylidene
4
deltacortene
4
azathiopurine
4
auricularum
4
Specimen Handling
4
Leucovorin
4
Asparaginase
4
Thioguanine
3
Rituximab
3
N,N-dicyclohexyl-isoborneol-10-sulfonamide
3
Methylprednisolone
3
fludarabine
2
calaspargase pegol
2
asparaginase erwinia chrysanthemi recombinant
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
×
navitoclax
×
Clear all
NCT05740449
2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2
Withdrawn